Navidea Biopharmaceuticals (NASDAQ: NAVB) envisions a world where disease can be precisely identified and treated. Navidea is a leader in precision medicine with products  designed to help identify the sites and pathways of  undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying its Manocept technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. For more information, visit the company’s website at www.navidea.com.